伴有或不伴有羟基脲治疗的中间型β地中海贫血患者的甲状腺功能减退症
Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea.
作者信息
Zekavat Omid Reza, Makarem Ali Reza, Haghpanah Sezaneh, Karamizadeh Zohreh, Javad Parvin, Karimi Mehran
机构信息
Hematology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran;
Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran;
出版信息
Iran J Med Sci. 2014 Jan;39(1):60-3.
Hydroxyurea (HU) has been successfully used in patients with β-thalassemia intermedia (β-TI). We aimed to evaluate the effect of the long-term use of HU on thyroid function in patients with β-TI. Seventy-five patients with β-TI aged≥11 years and taking HU were randomly selected during 2010 in southern Iran. Thirty-one patients with β-TI without HU were considered as a control group. Serum levels of thyroid stimulating hormone (TSH) and T4 were measured. The mean age of the participants was 22.7±5.1 years (age range=12-41 years). Serum ferritin level had no significant correlation with HU consumption (P>0.05). Overall, we detected 10 (9.4%) patients with hypothyroidism. We found that the use of HU at a dose of 8-15 mg/kg/day has no significant association with thyroid function in β-TI patients. However, due to the small sample size in our study, documentation of this finding needs further studies with higher numbers of patients.
羟基脲（HU）已成功应用于中间型β地中海贫血（β-TI）患者。我们旨在评估长期使用HU对β-TI患者甲状腺功能的影响。2010年在伊朗南部随机选取了75例年龄≥11岁且正在服用HU的β-TI患者。31例未服用HU的β-TI患者被视为对照组。检测血清促甲状腺激素（TSH）和T4水平。参与者的平均年龄为22.7±5.1岁（年龄范围=12 - 41岁）。血清铁蛋白水平与HU的服用无显著相关性（P>0.05）。总体而言，我们检测到10例（9.4%）甲状腺功能减退患者。我们发现，每天以8 - 15 mg/kg的剂量使用HU与β-TI患者的甲状腺功能无显著关联。然而，由于我们研究中的样本量较小，这一发现的记录需要更多患者的进一步研究。
Zotero 插件